Indeed, sclerostin-antibody treatment altered the number and activity of osteoblasts and osteoclasts in vivo, protected against cancer-induced bone destruction, and reduced the bone-metastatic burden in mouse models of breast cancer bone metastasis [29]. This evidence concerns the gene SOST and cancer.